Sai Life Sciences
Sai Life Sciences, a prominent player in the pharmaceutical and biotechnology sectors, is headquartered in Hyderabad, India. Founded in 1999, the company has established itself as a leading Contract Research and Manufacturing Services (CRAMS) provider, catering to global clients in drug discovery, development, and manufacturing. With a strong presence in key operational regions including North America and Europe, Sai Life Sciences offers a comprehensive range of services, from custom synthesis to formulation development. The company is recognised for its commitment to quality and innovation, which has earned it a solid market position and numerous accolades within the industry. Sai Life Sciences continues to drive advancements in life sciences, making significant contributions to the development of new therapeutics.
DitchCarbon Score
How does Sai Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sai Life Sciences's score of 33 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sai Life Sciences's reported carbon emissions
In 2024, Sai Life Sciences reported total carbon emissions of approximately 15,640,000 kg CO2e for Scope 1 and about 15,966,000 kg CO2e for Scope 2. Additionally, their Scope 3 emissions included approximately 1,240,000 kg CO2e from employee commuting, 487,000 kg CO2e from business travel, 1,734,000 kg CO2e from upstream transportation and distribution, and 589,000 kg CO2e from downstream transportation and distribution. For 2023, the company recorded Scope 1 emissions of about 12,610,200 kg CO2e and Scope 2 emissions of approximately 17,536,600 kg CO2e. Notably, their Scope 3 emissions were reported as a negative value of -4,050,000 kg CO2e, indicating a potential reduction in emissions from purchased goods and services, capital goods, and other categories. Sai Life Sciences has set ambitious climate commitments, aiming for a near-term reduction of 58.8% in absolute Scope 1 and 2 GHG emissions by FY2035, using FY2024 as the base year. They also target a 63.8% reduction in Scope 3 emissions per INR value added within the same timeframe. Furthermore, the company has committed to achieving net-zero CO2 emissions by around 2050, with an alternative scenario projecting net-zero emissions after 2070. These targets align with industry standards for climate action, reflecting Sai Life Sciences's commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 15,345,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 19,878,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | -0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sai Life Sciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
